神州细胞：预计2025年年度净利润亏损5.8亿元到5.2亿元

Core Viewpoint - Shenzhou Cell is expected to report a net loss attributable to shareholders of the parent company for the year 2025, ranging from -580 million to -520 million yuan, compared to the previous year [1] Group 1: Financial Performance - The company anticipates a significant decline in sales revenue due to ongoing healthcare cost control policies and multiple price reductions of its core product, Anjiah [1] - Overall operating revenue is expected to decrease compared to the same period last year [1] Group 2: Investment and Expenses - To facilitate market access and channel development for newly approved products, the company has increased upfront commercialization investments, including academic promotion and sales team formation, leading to a noticeable rise in sales expenses in the short term [1] - The company maintains a high level of research and development investment, with several ongoing projects entering critical confirmatory clinical trial stages during the reporting period [1]